Cryptosporidium parvum
is a highly prevalent zoonotic and anthroponotic protozoan parasite that causes a diarrheal syndrome in children and neonatal livestock, culminating in growth retardation and mortalities. Despite the high prevalence of
C
.
parvum
, there are no fully effective and safe drugs for treating infections, and there is no vaccine. We have previously reported that the bacterial-like
C
.
parvum
lactate dehydrogenase (CpLDH) enzyme is essential for survival, virulence and growth of
C
.
parvum in vitro
and
in vivo
. In the present study, we screened compound libraries and identified inhibitors against the enzymatic activity of recombinant CpLDH protein
in vitro
. We tested the inhibitors for anti-
Cryptosporidium
effect using
in vitro
infection assays of HCT-8 cells monolayers and identified compounds NSC158011 and NSC10447 that inhibited the proliferation of intracellular
C
.
parvum in vitro
, with IC
50
values of 14.88 and 72.65 μM, respectively. At doses tolerable in mice, we found that both NSC158011 and NSC10447 consistently significantly reduced the shedding of
C
.
parvum
oocysts in infected immunocompromised mice’s feces, and prevented intestinal villous atrophy as well as mucosal erosion due to
C
.
parvum
. Together, our findings have unveiled promising anti-
Cryptosporidium
drug candidates that can be explored further for the development of the much needed novel therapeutic agents against
C
.
parvum
infections.